Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma

Bone Marrow Transplantation volume 52, pages 1208–1211 (2017)Cite this article

Subjects

High-dose chemotherapy and autologous hematopoetic cell transplantation can rescue no more than 50% of patients with relapsed/refractory (RR) Hodgkin lymphoma (HL).1, 2 The novel anti-CD30 brentuximab vedotin (BV), the anti-PD1 nivolumab or pembrolizumab, and allogeneic (allo)-HCT represent treatment options in this subset. Importantly, the 2015 European and American guidelines recommend reduced-intensity conditioning allo-HCT for eligible patients relapsed after an autologous hematopoetic cell transplantation.3, 4

We present a long-term follow-up analysis on 69 consecutive RR HL patients treated with allo-HCT, between May 2000 and December 2015, at three Transplant Centers in Northwest Italy (AOU Città della Salute e della Scienza of Torino, AO Santa Croce e Carle of Cuneo, and AO Santi Antonio, Biagio e Cesare Arrigo of Alessandria).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Rancea M, von TB, Monsef I, Engert A, Skoetz N . High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis. Crit Rev Oncol Hematol 2014; 92: 1–10.

    Article  PubMed  Google Scholar 

  2. Martino M, Festuccia M, Fedele R, Console G, Cimminiello M, Gavarotti P et al. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. Expert Opin Biol Ther 2016; 16: 347–364.

    Article  CAS  PubMed  Google Scholar 

  3. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe. Bone Marrow Transplant 2015; 50: 1037–1056.

    Article  CAS  PubMed  Google Scholar 

  4. Perales MA, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21: 971–983.

    Article  PubMed  Google Scholar 

  5. Baron F, Little M-T, Storb R . Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev 2005; 19: 153–164.

    Article  PubMed  Google Scholar 

  6. Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablatvie conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1279–1287.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience. Haematologica 2008; 93: 257–264.

    Article  CAS  PubMed  Google Scholar 

  8. Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009; 15: 109–117.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol 2016; 27: 2251–2257.

    Article  CAS  PubMed  Google Scholar 

  10. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant 2014; 49: 190–194.

    Article  CAS  PubMed  Google Scholar 

  12. Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115: 3671–3677.

    Article  CAS  PubMed  Google Scholar 

  13. Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94: 230–238.

    Article  PubMed  Google Scholar 

  14. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934–1941.

    Article  PubMed  Google Scholar 

  15. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455–462.

    Article  CAS  PubMed  Google Scholar 

  16. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183–2189.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812–1821.

    Article  CAS  PubMed  Google Scholar 

  18. Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jager U et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012; 120: 1470–1472.

    Article  CAS  PubMed  Google Scholar 

  19. Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F et al. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica 2013; 98: 1232–1236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012; 120: 560–568.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Chen R, Palmer JM, Tsai NC, Thomas SH, Siddiqi T, Popplewell L et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 2014; 20: 1864–1868.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Garciaz S, Coso D, Peyrade F, Furst S, Duran S, Chetaille B et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Hematol Oncol 2014; 32: 187–191.

    Article  CAS  PubMed  Google Scholar 

  23. Tsirigotis P, Danylesko I, Gkirkas K, Shem-Tov N, Yerushalmi R, Stamouli M et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51: 1313–1317.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Progetti di Ricerca Finalizzata 2008–2009; Fondi di Ricerca Locale, Università degli Studi di Torino, Torino, Italy and by Fondazione Neoplasie del sangue (FO.NE.SA), Torino, Italy. We thank Maria Josè Fornaro and Sara Manetta for excellent secretarial support.

Author contributions

LG, MF, FZ, NM and BB designed the study. LG, MF and BB wrote the report. NM, MP, AB and BB supervised the clinical conduction of the study and data analysis. LG, MF, RS, NM, FZ and MP supervised data collection, analyzed data, and reviewed and assisted in writing the manuscript. LG, MF, FZ, RS, LB, EM, CD, GI, SA, MB, UV, NM, MP, AB and BB recruited the patients. RP did the statistical analysis.

Author information

Author notes

  1. L Giaccone and M Festuccia: These authors contributed equally to this work.

Authors and Affiliations

  1. Dipartimento di Oncologia, AOU Città della Salute e della Scienza di Torino, SSD Trapianto allogenico di cellule staminali, Torino, Italy

    L Giaccone, E Maffini, C Dellacasa, A Busca & B Bruno

  2. Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università di Torino, Scuola di Medicina, Torino, Italy

    L Giaccone, L Brunello, E Maffini, M Boccadoro & B Bruno

  3. Dipartimento di Oncologia, AOU Città della Salute e della Scienza di Torino, Ematologia U, Torino, Italy

    M Festuccia, L Brunello & M Boccadoro

  4. AO Antonio e Biagio e C. Arrigo, SS Trapianti SC Ematologia, Alessandria, Italy

    F Zallio & M Pini

  5. AO Santa Croce e Carle, UO Ematologia, Cuneo, Italy

    R Sorasio & N Mordini

  6. Divisione di Medicina Nucleare 2, AOU Città della Salute e della Scienza di Torino, Torino, Italy

    R Passera

  7. Dipartimento di Oncologia, Ematologia, AOU Città della Salute e della Scienza di Torino, Torino, Italy

    G Iovino, S Aydin & U Vitolo

Authors
  1. L Giaccone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Festuccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Zallio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Sorasio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Brunello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Maffini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Dellacasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Passera
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Iovino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Aydin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Boccadoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. U Vitolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. N Mordini
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M Pini
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A Busca
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. B Bruno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Giaccone.

Ethics declarations

Competing interests

BB has received honoraria from Gilead, Pfizer, Celgene, Hospira and research support from Celgene, Pierre Fabre, ADIENNE, Hospira Italia, MSD Italia. MB has received research support, consultancy and scientific advisory board from Celgene and Janssen-Cilag. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giaccone, L., Festuccia, M., Zallio, F. et al. Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Bone Marrow Transplant 52, 1208–1211 (2017). https://doi.org/10.1038/bmt.2017.99

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.99

This article is cited by

Search

Advanced search

Quick links